PharmacoEconomics & Outcomes News 660 - 18 Aug 2012

■ Total use of atorvastatin (Lipitor and genericatorvastatin) increased 10% from the third to fourthquarter of 2011 despite the drug losing patentprojection, according to a report by DecisionResources. Entry of generic atorvastatin will likelycontinue to increase the overall share of the moleculein the treatment of dyslipidaemia. Generic atorvastatinis predicted to steal market share not only frombranded Lipitor but also from other branded andgeneric statins, especially generic simvastatin, becauseatorvastatin is perceived by physicians to havesuperior efficacy and confer greater cardiovascular riskprotection.Decision Resources. Total Atorvastatin Use Increased Following Lipitor PatentLoss. Media Release : 7 Aug 2012. Available from: URL: http://www.decisionresources.com 809140050

1

PharmacoEconomics & Outcomes News 18 Aug 2012 No. 6601173-5503/10/0660-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved